**PROGRAM OUTLINE:**

**Introduction to Oncology: Focus on Solid Tumors**  
October 21-22, 2015  
San Francisco, CA

[www.healthtech.com/ioc](http://www.healthtech.com/ioc)

**Description:**

Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed with emphasis on mode of action, dose intensity and chemotherapy regimes. The range of side effects of cancer treatments will be studied in detail. Quality of life issues in terms of overall assessment and result interpretation will also be discussed.

Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, ovarian and prostate cancer and melanoma. Each session will be presented by clinicians active in these areas and will focus on overall patient presentation and management and cancer diagnosis and staging. Following these sessions, our experts will lead delegates in interactive group discussions on the key issues relating to effective management of each tumor type.

The limitations of cytotoxic drugs currently available are well known. With this in mind, the course includes in-depth discussion on new drug development and identification of new pharmacological targets of particular interest and value. Clinical trial design issues will also be included.

**Topics include:**

- Cancer: terminology and classification  
- Introduction to anti-cancer drugs and side effects  
- New developments in cancer therapy  
- Introduction to the major tumor types: breast, lung, melanoma, upper GI, colorectal, ovarian and prostate cancer  
- Clinical trial issues in oncology

**Who Should Attend:**

Healthcare’s courses are designed for both medical and non-medical staff within the pharmaceutical industry. This course is suitable for clinical research, medical information, regulatory affairs, biometrics and strategic marketing personnel.

**Course Instructors:**

**John Chan, M.D.**  
Regional Director Gynecologic Oncology, Sutter Health  
Adjunct Clinical Professor, University of California San Francisco School of Medicine  
Adjunct Clinical Professor, Stanford School of Medicine
Jeffrey Crawford, M.D.
George Barth Geller Professor for Research in Cancer
Department of Medicine Co-Director
Solid Tumor Therapeutics Program, Duke Cancer Institute
Duke University Medical Center

Charles J. Ryan, M.D.
Professor of Clinical Medicine and Urology
USCF Helen Diller Family Comprehensive Cancer Center

Alan Venook, M.D.
Professor of Clinical Medicine
Division of Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Administrative/Venue Details:
The registration fee at CHI’s VIP Discount Rate is $4,037 USD (regular rate $4,750 USD). You save 15% off your registration by registering through Cambridge Healthtech Institute (CHI). This includes lunch and refreshments throughout the day. Accommodation costs are not included. Delegates can register online or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records. Details of the venue will be supplied on registration.

Schedule:
October 21: October 22:
8:15 am – 5:00 pm 8:15 am – 4:00 pm

Course Schedule at-a-Glance
DAY 1 – Wednesday, October 21: 8:15 am – 5:00 pm

Registration – Continental breakfast available
Welcome/Opening Remarks

Introduction to Cancer
• Clarification of terminology
• Classification of tumor types
• Principles of treatment and review of treatment options
  - Chemotherapy
  - Radiotherapy
  - Surgical intervention
• Adjuvant and neoadjuvant therapy
• Endpoint assessment (response/survival)
• Hematological malignancies

Tea/coffee

Clinical Trials - Overview

Introduction to Anti-Cancer Drugs and Side Effects
• Classification of anti-cancer drugs
• Mechanisms of action
• Mono vs. combination therapy
• Chemotherapy regimes
• Dose intensity and outcome

Melanoma Case Presentation and Discussion

Lunch

Prostate Cancer
• Epidemiology
• Patient presentation
• Diagnosis and management
• Treatment of localized disease
• Treatment of advanced disease – locally and metastatic

Prostate Cancer Case Presentations and Discussion

Tea/coffee

Breast Cancer
• Epidemiology
• Diagnosis and staging
• Review of surgical procedures
• Chemotherapeutic options
• Role of hormonal therapy

Breast Cancer Case Presentations and Discussion

5:00 Close of Day One

DAY 2 – Thursday, October 22: 8:15 am – 4:00 pm

Continental breakfast available

Colorectal Cancer
• Epidemiology
• Patterns of presentation
• Diagnosis and management
• Surgery
• Chemotherapy
• Other treatment options

Colorectal Cancer Case Presentations and Discussion

Tea/coffee

Upper Gastrointestinal (GI) Cancer (esophagus, stomach, pancreas)
• Epidemiology
• Patterns of presentation
• Diagnosis and management
• Surgery
• Chemotherapy
• Radiotherapy

**Upper GI Case Presentations and Discussion**

**Ovarian Cancer**
- Epidemiology
- Diagnosis and staging
- Review of surgical procedures
- Chemotherapeutic options
- Role of hormonal therapy

**Lung Cancer**
- Epidemiology
- Small cell vs. non small cell cancer
- Patient presentation
- Treatment options
  - surgery
  - chemotherapy
  - radiotherapy

**Melanoma**
- Epidemiology
- Classification
- Diagnosis, staging and prognosis
- Current treatment options, their strengths and limitation

**About our Course Instructors:**

**John K. Chan, M.D.**
Dr. John K. Chan is the Director of the Division of Gynecologic Oncology and Associate Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. He currently holds the John A. Kerner Distinguished Professorship in Gynecologic Oncology. Dr. Chan received his Medical Degree from the University of California, Los Angeles, followed by Residency in Obstetrics and Gynecology at the University of California, Irvine and Fellowship in Gynecologic Oncology at the University of California, Irvine and the MD Anderson Cancer Center.

His research focuses on developing new therapies for gynecologic cancers, including genomic therapy and targeted biologic therapies, as well as investigating the role of tumor-initiating cells in ovarian cancer. He is involved in outcomes-based studies examining the treatment and outcomes of ovarian and uterine cancer patients. Dr. Chan has also recently been appointed as the principal investigator for one of the largest advanced ovarian cancer clinical trials in the country, which is currently open through the Gynecologic
Oncology Group. He has received research funding from the National Institutes of Health and the Institute of Aging to study the effects of prophylactic surgery on ovarian cancer risk.

Dr. Chan is an active member of the Gynecologic Oncology Group Ovarian Cancer Committee and is serving as the study chair for three Gynecologic Oncology Group protocols. He has received numerous grants and awards, including those from the National Cancer Institute, the Ovarian Cancer Research Foundation, and the Gynecologic Oncology Group.

Dr. Chan was selected as a member of the Scientific Program Committee for the Society of Gynecologic Oncologists and has played a major role in organizing educational programs for national and international gynecologic cancer societies. He is an active member in numerous academic organizations including the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists. Dr. Chan has authored and co-authored nearly 100 manuscripts in journals including Gynecologic Oncology, Cancer, Obstetrics & Gynecology, Journal of Clinical Oncology, British Journal of Cancer, American Journal of Obstetrics and Gynecology, Lancet Oncology, Cancer Research, and Clinical Cancer Research. He is also the co-author of three textbooks in the field of Gynecologic Oncology.

Jeffrey Crawford, M.D.
Jeffrey Crawford is the George Barth Professor for Research in Cancer and Chief of Medical Oncology in the Department of Medicine at the Duke University Medical Center. Dr. Crawford earned his medical degree at Ohio State University, USA. He was an Intern, Junior and Senior Assistant Resident in Medicine, and a Hematology/Oncology fellow at Duke University. Dr. Crawford later became Chief Resident in Medicine at Duke University/Veteran’s Administration Medical Center, and also a Geriatric Fellow. He is board certified in Internal Medicine as well as in the Hematology and Oncology subspecialties.

Dr. Crawford’s research interests include new treatment approaches in lung cancer, supportive cancer therapies and clinical trials of hematopoietic growth factors, biological agents and targeted drug development. He has led many US trial investigations on various cancer drugs, several of which have resulted in FDA approval. He also holds several positions with the National Comprehensive Cancer Network (NCCN), including chair of the Myeloid Growth Factor Committee and member of the Clinical Trials Network Investigator Steering Committee.

Dr. Crawford is vice-chair of the respiratory committee of the Cancer and Leukemia Group B (CALGB) and is Principal Investigator in the CALGB for Duke. Dr. Crawford is the Principal Investigator for the Cancer Biology and Research T32 training grant at Duke. He has served multiple leadership roles in the American Society of Clinical Oncology (ASCO), the Multinational Association of Supportive Care
Dr. Crawford has authored or co-authored 145 scientific articles, 60 book chapters and reviews, 180 abstracts and is co-editor of the book “Cancer Supportive Care.” He serves on the editorial boards of several journals. Dr. Crawford has received the Outstanding Service Award, Cancer Care, Inc, NY, America’s Top Doctors Award, Castle Connolly Medical Ltd, the Wayne Rundles Award for Excellence in Clinical Research, the Joseph Greenfield Research Faculty Award and the Wendell Rosse Teaching Award.

Charles J. Ryan, M.D.

Dr. Charles J. Ryan is a medical oncologist specializing in the treatment of thoracic and urologic malignancies. As a physician In the Thoracic Oncology Program, Dr. Ryan treats patients with non-small cell lung cancer, small cell lung cancer, BAC, mediastinal tumors and pulmonary metastases.

Dr. Ryan is a member of the UCSF Helen Diller Family Comprehensive Cancer Center where he conducts research investigating the most promising targeted therapies and novel agents for the treatment of cancer. Dr. Ryan has served as a Principal Investigator on a number of clinical trials and has authored numerous articles on molecularly targeted therapies.

Dr. Ryan earned his medical degree at the University of Wisconsin School of Medicine, where he also completed a residency in internal medicine. He then was accepted into a prestigious clinical fellowship program at Memorial Sloan-Kettering Cancer Center (MSKCC) where he received advanced state-of-the-art training in medical oncology. At MSKCC, Dr. Ryan took care of patients with complex and challenging cancers, many of whom had been diagnosed with advanced lung cancer.

Alan Venook, M.D.

Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at UCSF Medical Center where he leads the Gastrointestinal Oncology clinical program. He also is a professor of clinical medicine at UCSF and is the director of the UCSF Cancer Center Clinical Research Office at the Mount Zion site. His research focuses on treating liver tumors with directed approaches, including infusional chemotherapy or biological agents.

Dr. Venook earned a bachelor's degree from Rutgers University in 1976 and graduated from the UCSF
School of Medicine in 1980. He spent two years in the Public Health Service following internship, and trained in internal medicine at the University of California, Davis and in hematology and oncology at UCSF. He has been on the medical staff at UCSF since 1988.
Course Registration Form

Introduction to Cancer: Focus on Oncology
October 21-22, 2015
San Francisco, CA

Fill out and fax back to James Prudhomme at +1 781-972-5425

If you are paying by check or have any questions regarding payment, please call +1 781-972-5486. To inquire about a group discount, call +1 781-972-5472 or email cunningham@healthtech.com

Fee: VIP Discount Rate $4,037 USD (regular rate $4,750 USD). Hotel and travel costs are not included.

YOUR DETAILS:
Title: (tick applicable) ___ Dr. ___ Mr. ___ Mrs. ___ Ms. ___ Miss ___ Other
___________________________________________________________
First Name                                             Last Name
___________________________________________________________
Company                                               Job Title
___________________________________________________________
Department                                           Address
___________________________________________________________
City                                                  State       Country
___________________________________________________________
Telephone                                             Fax         Email
___________________________________________________________
Charge my credit card
___ VISA       ___ MasterCard       ___ American Express
___________________________________________________________
Name (as it appears on card)
___________________________________________________________
Account Number
___________________________________________________________
Start Date (mm/yy)                                        End Date (mm/yy)
___________________________________________________________
Security Number (from rear/front of card)
___________________________________________________________
Signature

Please note: No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more than 20 working days prior to course date will incur a $175 (USD) administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then please let us know.